(Q37529848)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Malignant pleural mesothelioma: current treatments and emerging drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

malignant pleural mesothelioma

1 February 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Dean Fennell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Monica Giovannini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Giovanni Gaudino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Luciano Mutti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

423-437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Simian virus 40 infection in humans and association with human diseases: results and hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

The European mesothelioma epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

The role of PET in the surgical management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Multimodality management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Patterns of failure following surgical resection for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Advances in the systemic therapy of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase II trial of ZD0473 as second-line therapy in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Angiogenesis is an independent prognostic factor in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Thalidomide in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

Influence of Radiotherapy Technique and Dose on Patterns of Failure for Mesothelioma Patients After Extrapleural Pneumonectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903074563

10.1517/14728210903074563

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19552609%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference